Through the use of artificial intelligence (AI) and imaging modalities such as ultrasound, CT, and MRI, the newly FDA-cleared VisAble.IO software reportedly enhances planning and real-time assessment for liver tumor ablation procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for VisAble.IO (TechsoMed), an artificial intelligence (AI)-enabled software that may facilitate improved real-time imaging guidance — through ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI) — for liver tumor ablation procedures.
TechsoMed said the software’s advanced computation and image registration elevate the planning and real-time assessment of liver tumor ablation.
The company noted that key benefits of the VisAble.IO software include:
• three-dimensional (3D) anatomical views of ablation targets;
• overlay positioning of virtual instruments and ablation region estimates onto imaging; and
• immediate post-procedure 3D views to assess ablation margins and potentially missed volumes.
“There is a real need for a good and efficient assessment tool, and (VisAble.IO) can serve any physician performing thermal ablations,” noted Ryosuke Tateishi, M.D., Ph.D., an associate professor in the Department of Gastroenterology at the University of Tokyo.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.